A 65-year-old man with longstanding seropositive rheumatoid arthritis and lower extremity ulceration

Arthritis Care and Research

Volumn 61, Issue 9, 2009, Pages 1275-1280

  Charabaty, Samar ^a   Shanmugam, Victoria ^a,b  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b 3PHC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ATORVASTATIN; CLOPIDOGREL; DIGOXIN; ENOXAPARIN; ESOMEPRAZOLE; FELODIPINE; HYDROXYCHLOROQUINE; METHOTREXATE; METOPROLOL; STEROID; TAMSULOSIN; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ADD ON THERAPY; AGED; ANAMNESIS; ARTERY DISEASE; CASE REPORT; CHOLESTEROL EMBOLISM; CONFERENCE PAPER; DRUG WITHDRAWAL; FOOT PAIN; FOOT ULCER; GANGRENE; HOSPITAL ADMISSION; HUMAN; JOINT SWELLING; LUNG EMBOLISM; LUPUS ERYTHEMATOSUS; MALE; METACARPOPHALANGEAL JOINT; MORNING STIFFNESS; PHYSICAL EXAMINATION; PLANTAR FASCIITIS; PODIATRIST; RHEUMATOID ARTHRITIS; SYNOVITIS; VASCULITIS;

AGED; AMPUTATION; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIAGNOSIS, DIFFERENTIAL; EMBOLISM, CHOLESTEROL; FOOT ULCER; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PERIPHERAL VASCULAR DISEASES; VASCULITIS;

EID: 69749091248     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24700     Document Type: Conference Paper

References (34)

1. Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore) 1981;60:288-297
2. Geirsson AJ, Sturfelt G, Truedsson L. Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications. Ann Rheum Dis 1987;46:727-733 (Pubitemid 17140293)
3. Vollertsen RS, Conn DL, Ballard DJ, Ilstrup DM, Kazmar RE, Silverfield JC. Rheumatoid vasculitis: survival and associated risk factors. Medicine (Baltimore) 1986;65:365-375 (Pubitemid 17201718)
4. Sayah A, English JC 3rd. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 2005;53:191-212. (Pubitemid 40979572)
5. Voskuyl AE, Zwinderman AH, Westedt ML, Vandenbroucke JP, Breedveld FC, Hazes JM. Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Ann Rheum Dis 1996;55:190-192
6. Van Albada-Kuipers GA, Bruijn JA, Westedt ML, Breedveld FC, Eulderink F. Coronary arteritis complicating rheumatoid arthritis. Ann Rheum Dis 1986;45:963-965 (Pubitemid 17178955)
7. Williams KJ. Molecular processes that handle - and mishandle - dietary lipids. J Clin Invest 2008;118:3247-3259
8. Del Rincon I, Freeman GL, Haas RW, O'Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005;52:3413-3423 (Pubitemid 41612207)
9. Liang KP, Liang KV, Matteson EL, McClelland RL, Christianson TJ, Turesson C. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum 2006;54:642-648 (Pubitemid 43228643)
10. Shanmugam VK, Steen VD, Cupps TR. Lower extremity ulcers in connective tissue disease. Isr Med Assoc J 2008;10:534-536
11. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-2179
12. Cunnane G, Warnock M, Fye KH, Daikh DI. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum 2002;47:445-449 (Pubitemid 34856135)
13. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000;27:2041-2044
14. Guillevin L, Mouthon L. Tumor necrosis factor-α blockade and the risk of vasculitis. J Rheumatol 2004;31:1885-1887 (Pubitemid 39336708)
15. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumor necrosis factor-α therapy-induced vasculitis: case series. J Rheumatol 2003;30:2287-2291 (Pubitemid 37221866)
16. Armstrong DJ, McCarron MT, Wright GD. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab [letter]. J Rheumatol 2005;32:759-760
17. Garcia-Porrua C, Gonzalez-Gay MA. Successful treatment of refractory mononeuritis multiplex secondary to rheumatoid arthritis with the anti-tumour necrosis factor α monoclonal antibody infliximab. Rheumatology (Oxford) 2002;41:234-235 (Pubitemid 34537908)
18. Unger L, Kayser M, Nusslein HG. Successful treatment of severe rheumatoid vasculitis by infliximab [letter]. Ann Rheum Dis 2003;62:587-588 (Pubitemid 36606297)
19. Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22:847-861
20. Sharma PV, Babu SC, Shah PM, Nassoura ZE. Changing patterns of atheroembolism. Cardiovasc Surg 1996;4:573-579
21. Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology 1987;38:769-784 (Pubitemid 17153204)
22. Falanga V, Fine MJ, Kapoor WN. The cutaneous manifestations of cholesterol crystal embolization. Arch Dermatol 1986; 122:1194-1198 (Pubitemid 16022288)
23. Orr WP, Banning AP. Aortic atherosclerotic debris detected by trans-oesophageal echocardiography: a risk factor for cholesterol embolization. QJM 1999;92:341-346
24. Bashore TM, Gehrig T. Cholesterol emboli after invasive cardiac procedures [editorial]. J Am Coll Cardiol 2003;42:217-218 (Pubitemid 36851408)
25. Hyman BT, Landas SK, Ashman RF, Schelper RL, Robinson RA. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987;82:1233-1237
26. Tunick PA, Nayar AC, Goodkin GM, Mirchandani S, Francescone S, Rosenzweig BP, et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 2002;90:1320-1325 (Pubitemid 35449477)
27. Sabatine MS, Oelberg DA, Mark EJ, Kanarek D. Pulmonary cholesterol crystal embolization. Chest 1997;112:1687-1692
28. Scolari F, Ravani P, Pola A, Guerini S, Zubani R, Movilli E, et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephrol 2003; 14:1584-1590 (Pubitemid 36687060)
29. Woolfson RG, Lachmann H. Improvement in renal cholesterol emboli syndrome after simvastatin. Lancet 1998;351:1331-1332 (Pubitemid 28195918)
30. Graziani G, Santostasi S, Angelini C, Badalamenti S. Corticosteroids in cholesterol emboli syndrome. Nephron 2001;87: 371-373
31. Motegi S, Abe M, Shimizu A, Tamura A, Hatori T, Nakano A, et al. Cholesterol crystal embolization: skin manifestation, gastrointestinal and central nervous symptom treated with corticosteroid. J Dermatol 2005;32:295-298 (Pubitemid 40745766)
32. Elinav E, Chajek-Shaul T, Stern M. Improvement in cholesterol emboli syndrome after iloprost therapy. BMJ 2002;324: 268-269 (Pubitemid 34121837)
33. Tamura K, Umemura M, Yano H, Sakai M, Sakurai Y, Tsurumi Y, et al. Acute renal failure due to cholesterol crystal embolism treated with LDL apheresis followed by corticosteroid and candesartan. Clin Exp Nephrol 2003;7:67-71. (Pubitemid 36460545)
34. Tsunoda S, Daimon S, Miyazaki R, Fujii H, Inazu A, Mabuchi H. LDL apheresis as intensive lipid-lowering therapy for cholesterol embolism [letter]. Nephrol Dial Transplant 1999;14: 1041-1042 (Pubitemid 29155188)